Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1

Conditions

Rectal Neoplasms 1Prostatic Neoplasms 1Neoplasms 1

Interventions

Early Intervention, Educational 5Radiotherapy 4Psychiatric Rehabilitation 4sargramostim 3pembrolizumab 3Trastuzumab 3Methods 3palbociclib 2cediranib 2Standard of Care 2Specimen Handling 2Mental Status and Dementia Tests 2Magnetic Resonance Spectroscopy 2Irinotecan 2Interleukin-12 Subunit p35 2Interferon-alpha 2Fluorouracil 2Fluorodeoxyglucose F18 2Erlotinib Hydrochloride 2Docetaxel 2Counseling 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1tipifarnib 1sapanisertib 1relatlimab 1pertuzumab 1osimertinib 1orantinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Rectal Neoplasms × Rifaximin × Genitourinary × Clear all
NCT06783153 2025-01-20

Efficacy and Safety of Adjunctive Use of Rifaximin In Preventing Radiotherapy-induced Diarrhea in Cancer Patients

Mansoura University

Phase 1/2 Not yet recruiting
80 enrolled
GastrointestinalGenitourinary

Neoplasms, Prostatic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡